Compare iShares MSCI Singapore ETF (EWS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Incyte Corporation — how do they compare? iShares MSCI Singapore ETF trades at $31.81, while Incyte Corporation trades at $116.19 (market cap $22.99B). Which is the better fit depends on your goals.
| EWS | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $118.52 |
52-Week Low | $26.47 | $67.38 |
Market Cap | — | $22.99B |
Enterprise Value | — | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS trades at $31.825, up 0.62% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from Singapore's economic resilience and AI-driven growth narrative, though key financial ratios remain undisclosed. Recent news highlights Singapore's strategic positioning in Asian markets and financial sector strength, with a dividend of $0.52 scheduled for June 2026.
Outlook remains positive given technical strength and regional economic tailwinds, but overbought RSI readings suggest near-term consolidation risk. The concentrated financials exposure (54% of holdings) ties performance to banking sector stability, while AI infrastructure investments offer growth catalysts. Investors should monitor Singapore's economic policies and global market volatility.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
